Recent Research Analysts’ Ratings Changes for MiMedx Group (MDXG)

Several brokerages have updated their recommendations and price targets on shares of MiMedx Group (NASDAQ: MDXG) in the last few weeks:

• 8/17/2026 – MiMedx Group was given a new $8.00 price target by Raymond James Financial, Inc..
• 8/17/2026 – MiMedx Group was downgraded by Seaport Research Partners to “neutral”.
• 8/17/2026 – MiMedx Group had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $8.00 price target on the stock.
• 8/13/2026 – MiMedx Group had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 8/1/2026 – MiMedx Group was downgraded by Wall Street Zen from “hold” to “sell”.

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

See Also

• Five stocks we like better than MiMedx Group
• Is Apple’s AI Strategy Smarter Than Skeptics Think?
• Why Lowe’s Could Be a Bargain Before Housing Recovers
• Okta’s AI Tailwind Could Put This Forgotten Software Stock Back in Play
• Datavault AI Locks Down CyberCatch in $94M Security Rollup